Dianthus Therapeutics develops experimental drugs for severe autoimmune diseases, led by the antibody claseprubart. DNTH reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in DNTH, 0% of them bullish and 100% bearish. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Roth Capital | Initiated | Buy | |
| Sep 11 | JP Morgan | Initiated | Buy | |
| Sep 4 | Citigroup | Initiated | Buy | |
| Aug 6 | Truist Securities | Maintained | Buy | |
| Aug 6 | HC Wainwright & Co. | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in DNTH in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DNTH is in one of them and how their past DNTH trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DNTH in an article yet. Here's the latest on the wider market.
About Dianthus Therapeutics
Dianthus Therapeutics is a biotechnology company based in New York that develops experimental drugs for people with severe autoimmune diseases. Its lead candidate, claseprubart, is an antibody that blocks the active form of the C1s protein, and it is designed to be injected under the skin at home. Its second candidate, DNTH212, is a fusion protein that targets two immune pathways involved in autoimmune disease. Both candidates are still in clinical trials and are not yet approved for sale.
- Headquarters
- New York, NY
- Website
- magentatx.com ↗